Accession Number : AD1007199


Title :   Transgastric Local Pancreatic Hypothermia: A Novel, Rapid Multimodal Therapy for Acute Pancreatitis


Descriptive Note : Technical Report,08 Jan 2015,07 Jan 2016


Corporate Author : Mayo Clinic Arizona Scottsdale United States


Personal Author(s) : Singh,Vijay P


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1007199.pdf


Report Date : 01 Feb 2016


Pagination or Media Count : 88


Abstract : Purpose: Study if transgastric local hypothermia of the pancreas reduces the metabolic demand of the pancreas during acute pancreatitis (AP) and AP severity. Scope: 1) Using metabolic imaging of the pancreas to predict its severity 2) Using transgastric cooling as a treatment modality for AP. These are proposed in Aim-3 of the grant. Time period of study: Jan to Dec 2015 Major Findings: 1) There is a significant increase in the uptake of Non-Radioactive Near Infra-Red 2-Deoxyglucose (IRDye (registered) 800CW 2-DG) in severe AP over controls which is detectable within an hour after AP induction without cooling. 2) Therapeutic transgastric hypothermia reduces severity in the GTL model of pancreatitis. Result: 1) Poster presented at the American Pancreatic Association annual meeting (November 2015) entitled; In Vivo Imaging of Non-Radioactive Near Infra-Red 2-Deoxyglucose During Mild and Severe Acute Pancreatitis (AP) in Rats. 2) Manuscript reviewed at PLOS ONE, minor issues addressed. The title is Characterization and predictive value of near infrared 2-deoxyglucose optical imaging in severe acute pancreatitis. Here we note that In-vivo fluorescent imaging of IRDye (registered) 800CW 2-DG can predict the AP severity early during the disease better than conventional markers of severe AP. Significance: Metabolic imaging of the pancreas can predict AP severity early in the disease. Ongoing studies: The studies in the intraductal GTL model are almost complete. We shortly will start studying this in the taurocholate model of AP and complete the other studies proposed.


Descriptors :   PANCREATIC DISEASES , PANCREAS , therapy


Distribution Statement : APPROVED FOR PUBLIC RELEASE